News from Bayer
June 28, 2022
Not intended for U.S. and UK Media
Bayer expands Radiology Business into AI Market with Calantic™ Digital Solutions
June 23, 2022
Vividion Therapeutics names Aleksandra Rizo as President and Head of Research and Development
June 21, 2022
Not intended for U.S. and UK Media
Rivaroxaban (Xarelto™) approved in Japan for patients with peripheral artery disease (PAD) after revascularisation
Explore All Stories
Please enter a term to search